Trials / Conditions / Steroid-refractory Acute Graft-versus-host Disease

Steroid-refractory Acute Graft-versus-host Disease

9 registered clinical trials studyying Steroid-refractory Acute Graft-versus-host Disease — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatm NCT06677255	Wuhan Optics Valley Vcanbiopharma Co., Ltd.	Phase 1 / Phase 2
Recruiting	Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. NCT06462469	Novartis Pharmaceuticals	Phase 4
Active Not Recruiting	Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory A NCT06075706	medac GmbH	Phase 2
Terminated	A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT NCT04934670	Xenikos	Phase 3
Recruiting	Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Ava NCT04629833	medac GmbH	Phase 3
Terminated	T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) NCT04128319	Xenikos	Phase 3
Completed	Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refra NCT03327857	AltruBio Inc.	Phase 1
Terminated	Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Re NCT02524847	Therakos, Inc., a Mallinckrodt Company	Phase 3
No Longer Available	Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After NCT03172455	Impatients N.V. trading as myTomorrows	—